COVID-19 trials registries data warehouse

 Return to trial list

Trial - JPRN-jRCTs031200374


Column Value
Trial registration number JPRN-jRCTs031200374
Full text link
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : July 16, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Hidetoshi Nomoto

Contact
Last imported at : July 16, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

covipla-rct@hosp.ncgm.go.jp

Registration date
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2021-02-24

Recruitment status
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not recruiting

Study design
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Open label

Center
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

unclear

Study aim
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Treatment

Inclusion criteria
Last imported at : Aug. 27, 2021, 9:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

(1) Patients who have given written consent to participate in the study from themselves or their guardians.(2) Hospitalized patients with a confirmed diagnosis of COVID-19 by PCR or LAMP, antigen testing, or other methods.(3) Patients who meet all of the following requirements at the time of admission.1)Within 5 days of onset2) SpO2 of 95% or higher in room air3) Aged 40 years or older or have one of the following underlying diseasesRenal dysfunction, chronic obstructive pulmonary disease (COPD), cardiac disease, cerebrovascular disease, malignancy, obesity, diabetes, hypertension, immunosuppressed state.(4) 20 years of age or older at the time of obtaining consent.(5) A person who is infected for the first time

Exclusion criteria
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

(1)Those who are pregnant or breastfeeding(2)Those whose religious beliefs do not support the administration of blood transfusions.(3)Those who are participating in an interventional study that provides therapeutic intervention for COVID-19.(4)Those who have been vaccinated against SARS-CoV-2.(5)Patients who have already received convalescent plasma.(6)Those with a history of allergy to blood products.(7)Patients with plasma protein deficiency such as IgA(8)Patients with NYHA class III or IV heart failure(9)Others who are judged inappropriate for inclusion in the study by the principal investigator, principal investigator, or sub-investigator.

Number of arms
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2

Funding
Last imported at : June 17, 2021, 12:45 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Sho Saito

Inclusion age min
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

20

Inclusion age max
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

100

Countries
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Japan

Type of patients
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Moderate disease at enrollment

Severity scale
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

3: Moderate disease at enrollment

Total sample size
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

200

primary outcome
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Time-weighted mean change in the amount of SARS-CoV-2 virus in nasopharyngeal swabs from day 0 to day 3 and day 5 of treatment

Notes
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase
Last imported at : Nov. 13, 2021, 5:33 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase 2/Phase 3

Arms
Last imported at : March 31, 2021, 4:03 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "", "treatment_id": 322, "treatment_name": "Convalescent plasma", "treatment_type": "Convalescent plasma", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]